BOTHELL, Wash., July 17, 2014 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media and precision thermal shipping products for cells and tissues ("BioLife" or the "Company"), today announced the execution of a long-term contract manufacturing services agreement with Somahlution LLC, a Jupiter, Florida-based biotechnology company.
Under the terms of the three-year agreement, BioLife will manufacture DuraGraft, a tissue preservation solution for storage of harvested veins used in coronary artery bypass graft (CABG) and other vascular access surgeries. Unlike existing potentially cyotocidal and clinically-unproven solutions, DuraGraft is the first Endothelial Damage Inhibitor (EDI) that uniquely protects vascular endothelium and its associated architecture. Financial terms of the agreement were not disclosed.
DuraGraft was marketed for several years under a different brand in more than 10,000 patients and Somahlution has compiled a significant body of clinical literature on its use.
"We are pleased to announce this new contract manufacturing agreement with Somahlution," said Mike Rice, BioLife President and CEO. "Their requirements and demand forecast are highly aligned with our manufacturing capacity and core expertise in aseptic formulation, fill, and finish of biopreservation media products. We understand their critical requirements and will work very hard to meet and exceed their expectations."
BioLife expects to complete process engineering and manufacturing validation to support product deliveries to Somahlution starting in the fourth quarter of 2014.
"DuraGraft is the pivotal success factor in bypass and vascular surgery and we felt that we needed to partner with a specialty CMO that understands our space and products," said Satish Chandran, Ph.D., Somahlution Chief Executive Officer. "BioLife's industry and product knowledge, customer relationship approach, and core expertise in aseptic media manufacturing are all factors that supported our decision to execute this important agreement with them. The potential addressable market for DuraGraft is very large and it was critical that we selected a partner that could meet our initial and anticipated future product demand."
The worldwide market potential for DuraGraft is based on CABG and Peripheral Vascular Bypass rates that are currently more than 0.1% of the population. Annually, 600,000 CABG and more than 500,000 peripheral vascular surgeries are performed in the US and EU.
Somahlution is a privately-held development-stage life science company focused on advancing the science of organ and surgical conduit transplantation. Led by a highly experienced team of executives, transplant researchers and surgeons, Somahlution's products and technologies have the potential to profoundly impact the landscape of transplant medicine. For more information please visit www.somahlution.com
About BioLife Solutions
BioLife Solutions develops, manufactures and markets hypothermic storage and cryopreservation solutions and precision thermal shipping products for cells, tissues, and organs. BioLife also performs contract aseptic media formulation, fill, and finish services. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. BioLife's enabling technology provides commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
This press release contains forward-looking statements, including, but not limited to, statements concerning our potential revenue growth, market size and market expansion. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including among other things, uncertainty regarding market adoption of our products; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations
Senior Vice President, Chief Financial Officer
SOURCE BioLife Solutions, Inc.